|Bid||0.00 x 3200|
|Ask||0.00 x 4000|
|Day's Range||5.33 - 5.80|
|52 Week Range||3.62 - 11.10|
|Beta (5Y Monthly)||1.70|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 03, 2021 - May 07, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.13|
Shares of Clovis Oncology (NASDAQ:CLVS) saw some unusual options activity on Tuesday. Following the unusual option alert, the stock price moved down to $6.22. Sentiment: BEARISH Option Type: TRADE Trade Type: PUT Expiration Date: 2021-03-19 Strike Price: $8.00 Volume: 200 Open Interest: 1522 Three Ways Options Activity Is ‘Unusual' Extraordinarily large volume (compared to historical averages) is one indication of unusual options market activity. Volume refers to the total number of contracts traded over a given time period when discussing options market activity. The number of contracts that have been traded, but not yet closed by either counterparty, is called open interest. A contract cannot be considered closed until there exists both a buyer and seller for it. The trading of a contract with an expiration date in the distant future is another sign of unusual activity. Generally, additional time until a contract expires increases the potential for it to reach its strike price and grow its time value. Time value is important in this context because it represents the difference between the strike price and the value of the underlying asset. "Out of the money" contracts are unusual because they are purchased with a strike price far from the underlying asset price. "Out of the money" occurs when the underlying price is under the strike price on a call option, or above the strike price on a put option. Buyers and sellers try to take advantage of a large profit margin in these instances because they are expecting the value of the underlying asset to change dramatically in the future. Understanding Sentiment Options are "bullish" when a call is purchased at/near ask price or a put is sold at/near bid price. Options are "bearish" when a call is sold at/near bid price or a put is bought at/near ask price. Although the activity is suggestive of these strategies, these observations are made without knowing the investor's true intentions when purchasing these options contracts. An observer cannot be sure if the bettor is playing the contract outright or if they're hedging a large underlying position in a common stock. For the latter case, the exposure a large investor has on their short position in common stock may be more meaningful than bullish options activity. Trading Options With These Strategies Unusual options activity is an advantageous strategy that may greatly reward an investor if they are highly skilled, but for the less experienced trader, it should remain as another tool to make an educated investment decision while taking other observations into account. For more information to understand options alerts, visit https://pro.benzinga.help/en/articles/1769505-how-do-i-understand-options-alerts See more from BenzingaClick here for options trades from BenzingaClovis Oncology: Q4 Earnings InsightsEarnings Scheduled For February 23, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Shares of Clovis Oncology (NASDAQ:CLVS) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share rose 59.12% year over year to ($0.74), which beat the estimate of ($0.77). Revenue of $43,299,000 up by 10.16% year over year, which beat the estimate of $43,220,000. Guidance Earnings guidance hasn't been issued by the company for now. Revenue guidance hasn't been issued by the company for now. Conference Call Details Date: Feb 23, 2021 View more earnings on CLVS Time: 08:30 AM ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fir.clovisoncology.com%2F&eventid=2948365&sessionid=1&key=FB0B2A9395DC1757937E4C97B2843680®Tag=&V2=false&sourcepage=register Recent Stock Performance 52-week high: $11.10 52-week low: $3.62 Price action over last quarter: Up 56.81% Company Overview Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidates include Rucaparib and Lucitanib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer whereas Lucitanib includes Rucaparib Combo and Nivolumab Combo. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 23, 2021Earnings Preview for Clovis Oncology© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2020, and provided an update on the Company’s clinical development programs and regulatory and commercial outlook for 2021.